The Motley Fool
05 Oct 2025, 12:41 UTC · 50w ago
Verdict
Headline leans bullish. We score NKTR +0.90 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Nektar Therapeutics' drug candidate rezpegaldesleukin showed 75% skin clearance in 62% of patients after 24 weeks in a Phase 2 trial.
So whatHigh efficacy results for a lead candidate in a large market (eczema) are primary drivers for biotech valuations.
More positive than 99% of claims this week
Rezpegaldesleukin's 16-week trial data (42% skin clearance) is competitive with the pivotal trial data for the market-leading drug Dupixent (44%).
So whatDemonstrating parity with a $14.2 billion revenue blockbuster suggests significant commercial potential.
Continue reading
5 related stories
More positive than 94% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
Nektar Therapeutics currently has no commercial-stage drugs generating revenue.
More negative than 87% of claims this week
The company must still complete a larger Phase 3 trial to confirm safety and efficacy.
More negative than 79% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Strong positive clinical trial data for its eczema candidate rezpegaldesleukin led to a massive stock price increase.
More negative than 69% of ticker scores this week
The company's market-leading drug Dupixent faces potential fierce competition from Nektar's new candidate.
More negative than 69% of ticker scores this week
The company's market-leading drug Dupixent faces potential fierce competition from Nektar's new candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
7h ago
More positive than 56% of relationship scores this week
[mutual] Nektar's rezpegaldesleukin is positioned to compete with Sanofi's Dupixent in the eczema treatment market.
More positive than 56% of relationship scores this week
[mutual] Nektar's rezpegaldesleukin is positioned to compete with Regeneron's Dupixent in the eczema treatment market.
−5.7%
Price is moving against the score
$57.09 vs $60.55 close before publication (Oct 3) · not market-adjusted
NKTR chart →
